Phase II trial of neoadjuvant osimertinib for surgically resectable EGFR -mutated non-small cell lung cancer. Read more about Phase II trial of neoadjuvant osimertinib for surgically resectable EGFR -mutated non-small cell lung cancer.
A phase 1/2 dose escalation study of the BCL-2 inhibitor ZN-d5 and the WEE1 inhibitor azenosertib (ZN-c3) in patients (Pts) with acute myeloid leukemia (AML). Read more about A phase 1/2 dose escalation study of the BCL-2 inhibitor ZN-d5 and the WEE1 inhibitor azenosertib (ZN-c3) in patients (Pts) with acute myeloid leukemia (AML).
Representativeness of patients with lung cancer in an integrated health care delivery system. Read more about Representativeness of patients with lung cancer in an integrated health care delivery system.
Patient-level factors associated with the use of active surveillance: The talking about prostate cancer cohort. Read more about Patient-level factors associated with the use of active surveillance: The talking about prostate cancer cohort.
Examining ultrafine particle pollution and lung cancer risk in a large, diverse cohort. Read more about Examining ultrafine particle pollution and lung cancer risk in a large, diverse cohort.
Associations between plant-based diets and risk of disease progression in men with prostate cancer. Read more about Associations between plant-based diets and risk of disease progression in men with prostate cancer.
Disparities in germline testing by race/ethnicity and preferred language in patients with prostate cancer. Read more about Disparities in germline testing by race/ethnicity and preferred language in patients with prostate cancer.
Association of biomarkers and response to immune checkpoint inhibitors (ICIs) in patients with metastatic urothelial carcinoma (mUC) with high and low tumor mutation burden (TMB). Read more about Association of biomarkers and response to immune checkpoint inhibitors (ICIs) in patients with metastatic urothelial carcinoma (mUC) with high and low tumor mutation burden (TMB).
Association of biomarkers and outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) treated with immune checkpoint inhibitors (ICIs). Read more about Association of biomarkers and outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) treated with immune checkpoint inhibitors (ICIs).
Use of high-dimensional and spatial immune profiling to explore sotigalimab (CD40 agonist) activation of antigen presenting cells and T cells in the tumor microenvironment in patients with esophageal/gastroesophageal junction cancer. Read more about Use of high-dimensional and spatial immune profiling to explore sotigalimab (CD40 agonist) activation of antigen presenting cells and T cells in the tumor microenvironment in patients with esophageal/gastroesophageal junction cancer.
